Results 231 to 240 of about 5,436,787 (348)

Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy. [PDF]

Int J Mol Sci
Jones AP, Zhao Y, Rueda BR, Yeku OO, Xu L.   +4 more
europepmc   +1 more source

Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor‐Associated Neutrophils to Sensitize Immunotherapy

Advanced Science, EarlyView.
The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang, Xinyu Qu, Tingting Ren, Tong Wu, Weiyong Gu, Jingxin Ding, Keqin Hua, Junjun Qiu   +7 more
wiley   +1 more source

Hypofractionated short course radiation therapy for recurrent ovarian cancer. [PDF]

Gynecol Oncol Rep
Miller EA, Kulkarni A, Lin JF, Cantillo E, Frey MK, Chapman-Davis E, Cardenes H, Holcomb K.   +7 more
europepmc   +1 more source

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

New England Journal of Medicine, 2003
Lin Zhang, J. Conejo-Garcia, D. Katsaros, P. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. Liebman, S. Rubin, G. Coukos   +11 more
semanticscholar   +1 more source

Halorotetin B, A Novel Terpenoid Compound Derived from Marine Ascidian, Suppresses Tumor Growth by Targeting the Cell Cycle Regulator UBE2C

Advanced Science, EarlyView.
Halorotetin B, a novel small‐molecule terpenoid identified from an edible marine ascidian, exhibits strong anti‐tumor activity both in vitro and in vivo through direct targeting UBE2C to induce tumor cell cycle arrest and then lead tumor cell senescence. As a newly discovered UBE2C inhibitor, Halorotetin B can serve as a novel potential cell senescence
Shanhao Han, Jianhui Li, Yuting Zhu, Penghui Liu, Yaoyao Zheng, Muchun He, Bo Dong   +6 more
wiley   +1 more source

Recent Advances in the Applications of Biomaterials in Ovarian Cancer. [PDF]

Biomimetics (Basel)
Mahfuz AMUB, Janorkar AV, Rocconi RP, Duan Y.   +3 more
europepmc   +1 more source

Stimuli‐Responsive Supramolecular Biomaterials for Cancer Theranostics

Advanced Science, EarlyView.
The ultimate goal of cancer theranostics is to get imaging agents and therapeutic cargo to tumor sites when and where they are required. “Smart” systems should be developed. This review discusses the characteristics of physiological stimuli, types and action modes of external stimuli, construction approaches and working principles, as well as ...
Wenting Hu, Binglin Ye, Guocan Yu, Feihe Huang, Zhengwei Mao   +4 more
wiley   +1 more source

Targeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy. [PDF]

Cancers (Basel)
Balan D, Kampan NC, Shafiee MN, Plebanski M, Abd Aziz NH.   +4 more
europepmc   +1 more source

DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway

Advanced Science, EarlyView.
Lenvatinib resistance poses a major challenge in advanced hepatocellular carcinoma (HCC). This study reveals that DNMT2 upregulation is a key driver, which stabilizes ACLY mRNA via m5C modification and activates the Notch signaling pathway. Crucially, combining ACLY inhibitors with lenvatinib overcomes resistance and suppresses tumors, offering a ...
Shiguang Yang, Jie Li, Shengwei Mao, Xuhui Zhao, Douwaner Liu, Jiafeng Chen, Jialu Fu, Yichao Bu, Xiaoling Wu, Shaoqing Liu, Qifeng Yu, Qiongzhu Dong, Zheng Tang, Yuan Fang, Yinghong Shi   +14 more
wiley   +1 more source

Metastasis of Ovarian Cancer to the Duodenum: A Case Report. [PDF]

Surg Case Rep
Maehira H, Mori H, Shiroyama R, Nitta N, Amano T, Tsuji S, Maekawa T, Sonoda T, Kaida S, Miyake T, Takebayashi K, Kojima M, Otake R, Tani S, Tani M.   +14 more
europepmc   +1 more source